William Pao to replace Roche's departing head of pRED

9 March 2018

Swiss pharma giant Roche (ROG: SIX) today announced that Dr John Reed head of Roche Pharma Research and Early Development (pRED) since 2013, has decided to leave Roche for personal reasons and will return to the USA effective April 2, 2018.

Dr William Pao, currently global head of the oncology discovery and translational area for pRED, has been appointed the new head of Roche pRED and will become a member of the enlarged corporate executive committee. He will be based in Basel and assume his new role on 2 April 2018.

Commenting on the appointment, Roche's chief executive Severin Schwan noted: "I am delighted with the appointment of one of our most distinguished scientific leaders, William Pao….Since joining Roche in 2014, William has been instrumental in the build-up of cancer immunotherapy and molecular targeted therapies….I am thankful to have had John Reed with Roche over the past five years, and for all his many valuable contributions. I wish John all the best for his future."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK